Drug or treatment

Apatinib clinical trials

• 57Clinical trials
• 1Country

Newest trials

All recruiting trials (57)

• First-line combo therapy with GnP, SHR-1701, and Apatinib for metastatic pancreatic cancer

  This trial tests whether adding SHR-1701 and Apatinib to standard GnP can safely and effectively treat previously untreated metastatic pancreatic cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07802184

• A combination therapy for advanced second-line gastric cancer using apatinib with albumin-bound paclitaxel, with or without adebrelimab

  This study tests whether adding adebrelimab to a regimen of apatinib and albumin-bound paclitaxel helps patients with advanced gastric or gastroesophageal junction cancer who did not respond to first-line therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07770113

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Alternating liver-artery and IV chemotherapy with optional adebrelimab and apatinib for unresectable biliary tract cancer

  This study will test whether alternating hepatic arterial infusion chemotherapy and standard IV gemcitabine–cisplatin, with or without the immunotherapy adebrelimab and the targeted drug apatinib, helps people with unresectable biliary tract cancer shrink tumors and live longer.

  Recruiting Phase 2 Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07569679

• Apatinib plus liposomal irinotecan for refractory or metastatic osteosarcoma

  This trial tests whether combining the oral drug apatinib with intravenous liposomal irinotecan helps patients whose osteosarcoma has progressed after standard chemotherapy.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing · NCT07479732

• Shr-1701 with or without Apatinib plus chemotherapy as neoadjuvant treatment for gastric cancer

  This trial tests whether adding SHR-1701, with or without apatinib, to chemotherapy before surgery helps patients with resectable locally advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07464756

• Adebrelimab and apatinib with SOX chemotherapy to make advanced stomach or GE junction cancer operable

  This treatment tests whether adding adebrelimab and apatinib to SOX chemotherapy can shrink advanced stomach or gastroesophageal junction adenocarcinomas so more people can have surgery.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07353684

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• Iparomlimab + Tuvonralimab with apatinib and irinotecan for AFP-producing advanced stomach or gastroesophageal junction cancer

  This study will test whether combining two immune drugs (iparomlimab and tuvonralimab) with apatinib and irinotecan helps people with advanced AFP-producing stomach or gastroesophageal junction cancer after progression on first-line PD-1 plus chemotherapy.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07289997

• Camrelizumab plus apatinib with or without FOLFOX chemotherapy for advanced liver cancer

  This research will test whether adding FOLFOX chemotherapy to camrelizumab plus apatinib helps adults with advanced hepatocellular carcinoma who have not received prior systemic treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07267806

• Apatinib and camrelizumab plus TACE before liver resection for centrally-located BCLC‑B hepatocellular carcinoma

  This trial tests whether giving apatinib and camrelizumab together with TACE before planned liver surgery can shrink tumors and improve outcomes for adults with centrally-located BCLC stage B hepatocellular carcinoma who are eligible for resection.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07154082

• Neoadjuvant fuzuloparib plus apatinib for HRD-positive advanced ovarian cancer

  This trial tests whether taking fuzuloparib together with apatinib before surgery helps people with HRD-positive advanced ovarian cancer shrink tumors and become eligible for successful surgery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07033819

• Perioperative radiotherapy with SOX chemotherapy plus apatinib and camrelizumab for esophagogastric cancer

  This trial tests whether adding apatinib and camrelizumab to SOX chemotherapy and radiotherapy before and after surgery helps adults with locally advanced gastric or GEJ adenocarcinoma.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07026149

• Combining Apatinib, Adebrelimab, and Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma

  This study is testing a new treatment that combines two medications with chemotherapy to see if it can help people with advanced liver cancer respond better than with standard chemotherapy alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06925516

• Comparing two treatment combinations for advanced gastric cancer

  This study is testing if adding a new drug called apatinib to standard treatments can help people with advanced gastric cancer get better results and stay safe during treatment.

  Recruiting at 4 sites Phase 3 Lanzhou University Second Hospital · Lanzhou, Gansu and 3 other locations · NCT06925243

• Camrelizumab plus apatinib and eribulin versus physician's choice chemotherapy for advanced triple-negative breast cancer

  This trial tests whether combining camrelizumab, apatinib, and eribulin works better than your doctor's chosen chemotherapy for adults with advanced triple-negative breast cancer who have had 1–4 prior systemic treatments.

  Recruiting at 5 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 6 other locations · NCT06889688

• Combining PD-1 inhibitor with Apatinib and Mitotane for advanced adrenal cancer treatment

  This study is testing a new combination of three medications to see if it can help people with advanced adrenal cancer who haven't had treatment yet.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06831175

• Combining Carilizumab and Apatinib for Advanced Gastric Cancer

  This study is testing if combining two medications, Carilizumab and Apatinib, can help people with advanced gastric cancer live longer without their disease getting worse.

  Recruiting Phase 2 Peking University Third Hospital · Beijing · NCT06792162

• Combining Adebrelimab with Apatinib and Gemcitabine/Cisplatin for treating advanced Biliary Tract Carcinoma

  This study is testing a new combination of treatments for patients with advanced biliary tract cancer to see if it helps them more than standard chemotherapy alone.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou · NCT06749730

• Combining liposomal irinotecan and apatinib for advanced small cell lung cancer

  This study is testing if combining two drugs, liposomal irinotecan and apatinib, can help people with advanced small cell lung cancer who haven't responded to their first treatment.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06749691

• Cryoablation combined with Karelizumab and Apatinib for lung cancer treatment

  This study is testing whether using cryoablation together with Karelizumab and Apatinib can safely help people with multiple primary lung cancers that lack known driver genes.

  Recruiting Phase 1/2 Guangzhou Institute of Respiratory Disease · Guangzhou, Guangdong · NCT06607770

• Combination therapy for advanced liver cancer patients

  This study is testing a new combination treatment for patients with advanced liver cancer to see if it can improve their chances of survival and how well they tolerate it.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06607107

• Combining Adbelimumab with Chemotherapy and Apatinib for Esophageal Cancer Treatment

  This study is testing a new treatment that combines Adbelimumab with chemotherapy and Apatinib to see if it can help people with esophageal cancer live longer and reduce the chances of cancer coming back after surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT06576973

• Combining TACE with Camrelizumab and Apatinib for Liver Cancer

  This study is testing if combining a liver cancer treatment called TACE with two drugs, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better compared to standard treatments.

  Recruiting Phase 3 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06485466

• Combining Adebrelimab, Apatinib Mesylate, and Chemotherapy for Treating Limited-stage Small Cell Lung Cancer

  This study is testing a new combination of a drug called adebrelimab, another drug called apatinib mesylate, and chemotherapy to see if it helps people with newly diagnosed limited-stage small cell lung cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06483282

• Using Adebrelimab and Apatinib for treating advanced small cell lung cancer

  This study is testing if a combination of Adebrelimab and Apatinib can help people with advanced small cell lung cancer live longer and feel better after their initial treatment.

  Recruiting China Medical University, China · Shenyang, Liaoning and 1 other locations · NCT06480864

• Combining Adebrelimab and Apatinib for Small Cell Lung Cancer Maintenance

  This study is testing if a combination of two drugs, Adebrelimab and Apatinib, can help people with extensive-stage small cell lung cancer stay healthy after their initial chemotherapy.

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT06475209

• Combining Adebrelimab and Apatinib for Liver Cancer Patients at High Risk of Recurrence

  This study is testing if combining two medications, Adebrelimab and Apatinib, can help liver cancer patients who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06454578

• Comparing two treatment regimens for high-risk nasopharyngeal carcinoma

  This study is testing a new combination of treatments for patients with high-risk nasopharyngeal cancer to see if it works better than the standard treatment.

  Recruiting at 2 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06438627

• Combining PD-L1 inhibitor with apatinib for treating advanced small cell lung cancer

  This study is testing if a new combination of a PD-L1 inhibitor and apatinib can help people with advanced small cell lung cancer stay cancer-free longer after their initial treatment.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06429696

• Combination treatment for HER2-negative breast cancer brain metastasis

  This study is testing a new combination treatment for patients with HER2-negative breast cancer that has spread to the brain to see if it can help shrink tumors and improve survival.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06418594

• Combining paclitaxel, apatinib, and adebrelimab for advanced gastric cancer treatment

  This study is testing a new combination of three drugs to see if it can help people with advanced stomach cancer who haven't had much success with other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Fuzhou, Fujian · NCT06415669

• Combining TAE+HAIC with Camrelizumab and Apatinib for Advanced Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it can help patients with high tumor loads feel better and improve their outcomes.

  Recruiting Phase 2 Fujian Medical University · Fuzhou · NCT06363825

• Combining radiotherapy with camrelizumab and apatinib for liver cancer treatment

  This study is testing if a combination of radiation therapy with two medications can help shrink liver cancer tumors before surgery for patients whose cancer has spread to the portal vein.

  Recruiting Phase 2 Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06349317

• Combination immunotherapy for advanced esophageal cancer

  This study is testing a new combination of treatments for patients with advanced esophageal cancer who haven't responded to previous therapies to see if it can help them.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06339619

• Treatment for resectable intrahepatic cholangiocarcinoma using a combination of drugs and chemotherapy

  This study is testing a new combination of drugs and chemotherapy to see if it can help people with resectable intrahepatic cholangiocarcinoma live longer and prevent the cancer from coming back after surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06296563

• Chemotherapy with Adebrelimab and Apatinib for Biliary Tract Cancer Treatment

  This study is testing a new combination of chemotherapy and two drugs, Adebrelimab and Apatinib, to see if it can help patients with a specific type of bile duct cancer who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, China/Guangdong · NCT06280508

• Combining cadonilimab and regorafenib for advanced liver cancer patients who didn't respond to previous treatment

  This study is testing if combining two drugs, cadonilimab and regorafenib, can help people with advanced liver cancer who didn't respond to earlier treatments.

  Recruiting Phase 2 Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06280105

• Fluzoparib plus apatinib versus physician-selected chemotherapy for HRD-positive, HER2-negative advanced breast cancer

  This trial will test whether combining the PARP inhibitor fluzoparib with the anti-angiogenic drug apatinib works better than doctors' choice chemotherapy for adults with HRD-positive, HER2-negative advanced breast cancer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06255392

• Combining adebrelimab with apatinib, gemcitabine, and cisplatin for treating biliary tract cancers

  This study is testing a new combination of medications to see if it can help people with high-risk biliary tract cancers do better before surgery.

  Recruiting Phase 1 First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06181032

• Comparing two treatment methods for advanced liver cancer

  This study is testing two different treatment methods for advanced liver cancer to see which one helps patients feel better and live longer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06172205

• New treatment approach for advanced nasopharyngeal carcinoma

  This study tests a new treatment combination for people with advanced nasopharyngeal cancer to see if it works better and is less harmful than the usual chemotherapy.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT05854849

• Combining Camrelizumab, Apatinib, and Temozolomide for Advanced Acral Melanoma Treatment

  This study is testing a new combination of three medications to see if it helps people with advanced acral melanoma live longer without their cancer getting worse compared to standard treatments.

  Recruiting Phase 3 Peking University Cancer Hospital & Institute · Beijing · NCT05789043

• Comparing Apatinib Mesylate to Standard Treatments for Advanced GIST

  This study is testing if a new drug called Apatinib Mesylate can work better than standard treatments for patients with advanced gastrointestinal stromal tumors who haven't had success with their first treatment.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT05751733

• Combining camrelizumab and apatinib with chemotherapy for advanced esophageal cancer

  This study is testing a new combination of two drugs and chemotherapy to see if it helps people with advanced esophageal cancer feel better compared to standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT05738434

• Combination therapy for advanced gastric cancer

  This study is testing a new combination of treatments for advanced gastric cancer to see if it works better than the standard treatment for patients with larger tumors.

  Recruiting Phase 2/3 Fujian Cancer Hospital · Fuzhou, Fujian · NCT05699655

• Combining camrelizumab and apatinib with TACE for liver cancer treatment

  This study is testing if combining two medications with a liver cancer treatment before surgery can help people with liver cancer live longer and have fewer problems after surgery.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05613478

• Combination therapy for high-risk acral melanoma before surgery

  This study is testing a new combination of treatments before surgery to see if it can help people with high-risk acral melanoma have better outcomes.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05512481

• Combining camrelizumab, apatinib, and chemotherapy for treating triple negative breast cancer

  This study tests if a new combination of camrelizumab, apatinib, and chemotherapy can help shrink tumors and improve outcomes for patients with early or locally advanced triple negative breast cancer before surgery.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT05447702

• Evaluating camrelizumab and apatinib mesylate for liver cancer treatment

  This study is testing whether a combination of two drugs, camrelizumab and apatinib mesylate, can help people with liver cancer that can't be surgically removed feel better and improve their health.

  Recruiting Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT05409482

• Camrelizumab plus apatinib for high‑risk gestational trophoblastic neoplasia

  This trial will test whether adding camrelizumab and apatinib to chemotherapy helps women with ultra high‑risk or chemo‑refractory/relapsed high‑risk gestational trophoblastic neoplasia achieve remission.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT05139095

• Surgery combined with immunotherapy and targeted therapy for advanced liver cancer

  This study is testing whether combining surgery with two treatments, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better.

  Recruiting Phase 2/3 Guangxi Medical University · Nanning · NCT05062837

• Camrelizumab plus apatinib for advanced gastric and gastroesophageal junction adenocarcinoma

  This trial tests whether combining camrelizumab and apatinib can help people with advanced gastric or gastroesophageal junction cancer that progressed after first-line platinum-based therapy, especially if their tumors are PD-L1 positive.

  Recruiting Phase 3 Jiangsu HengRui Medicine Co., Ltd. · Beijing · NCT04342910

• Neoadjuvant treatment for advanced acral melanoma

  This study is testing a new combination treatment for patients with advanced acral melanoma to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT04331093

• Using Apatinib to treat advanced or metastatic sarcoma with a specific genetic marker

  This study is testing if the drug Apatinib can help people with advanced bone and soft tissue sarcoma who have a specific genetic marker feel better and have fewer side effects.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT04072042

• Apatinib as first-line therapy for elderly with advanced or metastatic gastric cancer

  This study tests whether apatinib can help elderly patients with advanced gastric or gastroesophageal cancer who can’t or won’t have chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital of Bengbu Medical University · Bengbu, Anhui · NCT03219593

• A halting of malignant ascites with apatinib in patients with cancer-related ascites

  This trial tests whether daily oral apatinib can help people with cancer-related malignant ascites who have not responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Bengbu Medical University · Bengbu, Anhui · NCT03020979

Quick answers

How many clinical trials of Apatinib are recruiting right now?

57, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 36, Phase 3: 11, Phase 1/2: 3, Phase 2/3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →